出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2024年4月
Companion Diagnostics Market – Global Forecast To 2029
コンパニオン診断市場 : 製品（アッセイ、キット、試薬、システム、ソフトウェア＆サービス）、技術（PCR、NGS、ISH、IHC）、適応症（乳房、肺、結腸直腸がん、CVD、感染症、神経学）、サンプルの種類（組織、血液）＆地域別 – 2029年までの世界予測
Companion Diagnostics Market By Product (Assays, Kits, Reagents, System, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious, Neurology), Sample Type (Tissue, Blood) & Region – Global Forecast to 2029
| ページ数 | 349 |
| 図表数 | 433 |
| 価格 | |
| シングルユーザライセンス | USD 4,950 |
| マルチユーザライセンス（5名） | USD 6,650 |
| コーポレート（サイト）ライセンス | USD 8,150 |
| エンタープライズライセンス | USD 10,000 |
| 種別 | 英文調査報告書 |
Report Overview
The global companion diagnostics market is projected to reach USD 13.6 billion by 2029 from USD 7.5 billion in 2024, at a CAGR of 12.6% during the forecast period.
世界のコンパニオン診断市場は、予測期間中のCAGR 12.6%で、2024年の75億米ドルから2029年までに136億米ドルに達すると予測されています。
Factors such as the increasing importance of companion diagnostics in drug development, rising cancer incidence, and the growing adoption of targeted therapies are driving market growth.
“The assays, reagents & kits segment expected to achieve the highest growth rate in the companion diagnostics market, by product & service, during the forecast period”
The companion diagnostics market is categorized into assays, kits & reagents, instruments/systems and software & services based on product & service. In 2023, the assays, kits & reagents segment held the largest share of the market. This can be attributed to factors such as the wide range of available products, the rising utilization of assays and kits across various therapeutic fields, and the increasing demand for these products in both basic research and commercial applications.
“Pharmaceutical & biotechnology companies segment projected to account for the highest CAGR during the forecast period”
Based on end user, the companion diagnostics market is segmented into pharmaceutical & biotechnology companies, reference laboratories, CROs, and other end users.
In 2023, pharmaceutical & biotechnology companies stood out as the primary users of companion diagnostics within the market. This notable position is primarily attributed to the increasing adoption of companion diagnostics in drug development and the growing significance of companion diagnostic biomarkers. Furthermore, the rising interest in personalized medicine, along with the pressing need for targeted therapies across various diseases and disorders, is forecasted to boost the demand and integration of companion diagnostics among pharmaceutical & biotechnology companies.
“Asia Pacific: The fastest-growing region in companion diagnostics care market”
The global companion diagnostics market is divided into North America, Europe, Asia Pacific, Latin America, Middle East & Africa and the GCC Countries. The Asia Pacific region is expected to record the highest CAGR during the forecast period. This growth is attributed to factors such as increased healthcare expenditure, rising pharmaceutical research funding, government initiatives to raise awareness about early disease detection, expansion of private-sector hospitals into rural areas in various APAC countries, and the presence of high-growth markets in the region.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 20%, Tier 2 – 45%, and Tier 3 -35%
• By Designation: C-level – 30%, D-level – 20%, and Others – 50%
• By Region: North America – 42%, Europe – 31%, Asia Pacific – 20%, and Rest of the World -7%
Lists of Companies Profiled in the Report:
• F. Hoffmann-La Roche Ltd (Switzerland)
• Agilent Technologies, Inc. (US)
• QIAGEN (Netherlands)
• Thermo Fisher Scientific Inc. (US)
• Abbott (US)
• Almac Group (UK)
• Danaher (US
• Illumina, Inc. (US)
• bioMérieux (France)
• Myriad Genetics, Inc. (US)
• Sysmex Corporation (Japan)
• ARUP Laboratories (UK)
• Abnova Corporation (Taiwan)
• Guardant Health (US)
• ICON Plc (Ireland)
• BioGenex (US)
• Invivoscribe, Inc. (US)
• ArcherDX, Inc. (Integrated DNA Technologies, Inc.) (US)
• NG Biotech (France)
• Q² Solutions (US)
• Amoy Diagnostics Co., Ltd. (China)
• Uniogen (Abacus Diagnostica) (Finland)
• Asuragen, Inc. (Bio-Techne) (US)
• NG Biotech (France)
• Meso Scale Diagnostics, LLC. (US)
• Creative Biolabs (US)
Research Coverage:
This research report categorizes the companion diagnostics market by products, type, application and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the companion diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies; contracts, partnerships, agreements, new product launches, mergers and acquisitions, and recent developments associated with the companion diagnostics market. Competitive analysis of upcoming startups in the companion diagnostics market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall companion diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the companion diagnostics market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the companion diagnostics market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the companion diagnostics market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the companion diagnostics market.
• Competitive Assessment: In-depth assessment of market ranking, growth strategies and product offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), QIAGEN (Netherlands), Thermo Fisher Scientific Inc. (US) and Abbott (US).
Table of Contents
1 INTRODUCTION 46
1.1 STUDY OBJECTIVES 46
1.2 MARKET DEFINITION 46
1.2.1 INCLUSIONS & EXCLUSIONS 47
1.3 MARKET SEGMENTATION 48
1.3.1 MARKETS COVERED 48
1.3.2 REGIONS COVERED 49
1.3.3 YEARS CONSIDERED 49
1.4 CURRENCY CONSIDERED 50
1.5 RESEARCH LIMITATIONS 50
1.6 MARKET STAKEHOLDERS 50
1.7 SUMMARY OF CHANGES 51
1.7.1 RECESSION IMPACT 51
2 RESEARCH METHODOLOGY 52
2.1 RESEARCH DATA 52
2.2 RESEARCH APPROACH 52
FIGURE 1 RESEARCH DESIGN METHODOLOGY 52
2.2.1 SECONDARY DATA 53
2.2.1.1 Key data from secondary sources 54
2.2.2 PRIMARY DATA 55
2.2.2.1 Primary sources 55
2.2.2.2 Key data from primary sources 56
2.2.2.3 Key industry insights 57
2.2.2.4 Breakdown of primary interviews 57
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 57
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 58
2.3 MARKET SIZE ESTIMATION 58
2.3.1 BOTTOM-UP APPROACH 59
2.3.1.1 Approach 1: Company revenue estimation approach 59
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 59
2.3.1.2 Approach 2: Presentations of companies and primary interviews 59
2.3.1.3 Growth forecast 60
2.3.1.4 CAGR projections 60
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 60
2.3.2 TOP-DOWN APPROACH 60
FIGURE 6 COMPANION DIAGNOSTICS MARKET: TOP-DOWN APPROACH 61
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 62
FIGURE 7 DATA TRIANGULATION METHODOLOGY 62
2.5 STUDY ASSUMPTIONS 63
2.6 GROWTH RATE ASSUMPTIONS 63
2.7 LIMITATIONS 63
2.8 RISK ASSESSMENT 64
2.8.1 RISK ASSESSMENT ANALYSIS 64
2.9 RECESSION IMPACT ANALYSIS 64
3 EXECUTIVE SUMMARY 66
FIGURE 8 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION) 66
FIGURE 9 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION) 67
FIGURE 10 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION) 68
FIGURE 11 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024 VS. 2029 (USD MILLION) 69
FIGURE 12 COMPANION DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 69
FIGURE 13 COMPANION DIAGNOSTICS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION) 70
4 PREMIUM INSIGHTS 71
4.1 COMPANION DIAGNOSTICS MARKET OVERVIEW 71
FIGURE 14 GROWING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH 71
4.2 COMPANION DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2024 VS. 2029 71
FIGURE 15 ASSAYS, KITS, AND REAGENTS TO DOMINATE MARKET IN 2029 71
4.3 COMPANION DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2024 VS. 2029 72
FIGURE 16 POLYMERASE CHAIN REACTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 72
4.4 COMPANION DIAGNOSTICS MARKET SHARE, BY INDICATION, 2024 VS. 2029 72
FIGURE 17 CANCER SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 72
4.5 COMPANION DIAGNOSTICS MARKET SHARE, BY SAMPLE TYPE, 2024 VS. 2029 73
FIGURE 18 TISSUE SAMPLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 73
4.6 COMPANION DIAGNOSTICS MARKET SHARE, BY END USER, 2024 VS. 2029 73
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET IN 2029 73
4.7 COMPANION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 74
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN COMPANION DIAGNOSTICS MARKET DURING FORECAST PERIOD 74
5 MARKET OVERVIEW 75
5.1 INTRODUCTION 75
5.2 MARKET DYNAMICS 75
FIGURE 21 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 75
5.2.1 DRIVERS 76
5.2.1.1 Ability of CDx tests to reduce healthcare costs and increase efficiency 76
5.2.1.2 Growing focus on targeted therapy 76
5.2.1.3 Rising demand for personalized medicine 77
FIGURE 22 PERSONALIZED MEDICINE APPROVALS BY US FDA (2015−2022) 77
5.2.1.4 Increasing incidence of cancer and subsequent adoption of CDx-based oncology medicine 78
FIGURE 23 GLOBAL CANCER INCIDENCE (2008−2030) 78
TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES FOR BOTH GENDERS (AGE: 0–85+), 2022 VS. 2045 79
5.2.1.5 Growing application areas for companion diagnostics 79
5.2.2 RESTRAINTS 79
5.2.2.1 Significant capital investment and low cost-benefit ratio 79
5.2.2.2 High cost of companion diagnostic tests 80
5.2.2.3 Unfavorable reimbursements 80
TABLE 2 COMPANION DIAGNOSTICS MARKET: REIMBURSEMENT GUIDELINES ACROSS REGIONS 81
5.2.2.4 High cost of immunotherapy treatment 81
5.2.3 OPPORTUNITIES 82
5.2.3.1 Increasing demand for next-generation sequencing 82
TABLE 3 DEALS UNDERTAKEN FOR DEVELOPMENT OF NGS-BASED COMPANION DIAGNOSTIC TESTS 82
5.2.3.2 Growing significance of companion diagnostics in drug development 83
TABLE 4 LIST OF FDA-APPROVED DRUGS WITH CDX ASSAYS 83
5.2.3.3 Advancements in genomics research and rising clinical trials 83
5.2.4 CHALLENGES 84
5.2.4.1 Shortage of healthcare professionals 84
5.2.4.2 Limited awareness in emerging markets 84
5.3 PRICING ANALYSIS 85
TABLE 5 INDICATIVE PRICING FOR COMPANION DIAGNOSTICS PRODUCTS 85
TABLE 6 AVERAGE SELLING PRICE OF COMPANION DIAGNOSTICS PRODUCTS, BY REGION 85
5.4 PATENT ANALYSIS 86
FIGURE 24 PATENT ANALYSIS OF COMPANION DIAGNOSTICS SYSTEMS (JANUARY 2014–DECEMBER 2023) 86
5.5 TRADE ANALYSIS 87
5.5.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS 87
TABLE 7 IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS, BY COUNTRY, 2018−2022 (USD MILLION) 87
TABLE 8 EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS, BY COUNTRY, 2018−2022 (USD MILLION) 87
5.6 VALUE CHAIN ANALYSIS 87
FIGURE 25 VALUE CHAIN ANALYSIS: MAJOR VALUE-ADDED DURING MANUFACTURING & ASSEMBLY PHASES 88
5.7 SUPPLY CHAIN ANALYSIS 89
FIGURE 26 COMPANION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 89
5.8 ECOSYSTEM ANALYSIS 90
FIGURE 27 ECOSYSTEM MAP 90
TABLE 9 COMPANION DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 90
5.9 PORTER’S FIVE FORCES ANALYSIS 91
TABLE 10 COMPANION DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 91
5.9.1 THREAT OF NEW ENTRANTS 91
5.9.2 THREAT OF SUBSTITUTES 91
5.9.3 BARGAINING POWER OF BUYERS 91
5.9.4 BARGAINING POWER OF SUPPLIERS 92
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 92
5.10 REGULATORY LANDSCAPE 92
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 12 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 13 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
5.10.2 NORTH AMERICA 94
5.10.2.1 US 94
5.10.2.2 Canada 94
5.10.3 EUROPE 94
TABLE 15 EUROPE: CLASSIFICATION OF DEVICES 95
5.10.4 ASIA PACIFIC 95
5.10.4.1 China 95
5.10.4.2 Japan 95
TABLE 16 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 96
5.10.4.3 India 96
5.10.5 LATIN AMERICA 96
5.10.5.1 Brazil 96
5.10.5.2 Mexico 97
5.10.6 MIDDLE EAST 97
5.10.7 AFRICA 97
5.11 TECHNOLOGY ANALYSIS 97
5.11.1 KEY TECHNOLOGIES 98
5.11.1.1 Polymerase chain reaction (PCR) 98
5.11.1.2 Next-generation sequencing (NGS) 98
5.11.2 COMPLIMENTARY TECHNOLOGIES 98
5.11.2.1 In situ hybridization (ISH) 98
5.11.3 ADJACENT TECHNOLOGIES 98
5.11.3.1 Immunohistochemistry (IHC) 98
5.12 KEY CONFERENCES & EVENTS IN 2024–2025 99
TABLE 17 COMPANION DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 99
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 100
5.13.1 REVENUE POCKETS FOR COMPANION DIAGNOSTICS MARKET 100
FIGURE 28 REVENUE SHIFT FOR COMPANION DIAGNOSTICS MARKET 100
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 101
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 101
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF COMPANION DIAGNOSTICS PRODUCTS 101
TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR COMPANION DIAGNOSTICS PRODUCTS (%) 101
5.14.2 BUYING CRITERIA 102
FIGURE 30 KEY BUYING CRITERIA FOR COMPANION DIAGNOSTICS PRODUCTS 102
TABLE 19 KEY BUYING CRITERIA FOR COMPANION DIAGNOSTICS PRODUCTS 102
5.15 INVESTMENT AND FUNDING SCENARIO 103
FIGURE 31 COMPANION DIAGNOSTICS MARKET: INVESTMENT & FUNDING SCENARIO 103
6 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 104
6.1 INTRODUCTION 105
TABLE 20 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 105
6.2 ASSAYS, KITS, AND REAGENTS 105
6.2.1 INCREASING VOLUME OF CDX TESTS IN LABORATORIES TO SUPPORT ADOPTION OF ASSAYS & KITS 105
TABLE 21 ASSAYS & KITS: PRODUCTS OFFERED, BY COMPANY 106
TABLE 22 COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY REGION, 2022–2029 (USD MILLION) 107
TABLE 23 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 24 EUROPE: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 25 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 26 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION) 109
6.3 INSTRUMENTS & SYSTEMS 109
6.3.1 LATEST ADVANCEMENTS IN NGS TECHNOLOGIES TO ENSURE MARKET GROWTH 109
TABLE 27 INSTRUMENTS & SYSTEMS: PRODUCTS OFFERED, BY COMPANY 110
TABLE 28 COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY REGION, 2022–2029 (USD MILLION) 110
TABLE 29 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 30 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 31 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 32 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION) 112
6.4 SOFTWARE & SERVICES 112
6.4.1 NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTICS TESTS TO SUPPORT MARKET GROWTH 112
TABLE 33 SOFTWARE & SERVICES: PRODUCTS OFFERED, BY COMPANY 113
TABLE 34 COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2022–2029 (USD MILLION) 113
TABLE 35 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 36 EUROPE: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION 114
TABLE 37 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 38 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION) 115
7 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY 116
7.1 INTRODUCTION 117
TABLE 39 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 117
7.2 POLYMERASE CHAIN REACTION 117
7.2.1 GROWING APPLICATIONS IN PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE GROWTH 117
TABLE 40 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION 118
TABLE 41 MAJOR PCR TESTS/KITS AVAILABLE 118
TABLE 42 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022–2029 (USD MILLION) 119
TABLE 43 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION) 119
TABLE 44 EUROPE: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 45 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 46 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION) 121
7.3 IN SITU HYBRIDIZATION 121
7.3.1 INCREASING DEMAND IN SMALL TUMOR DIAGNOSTICS TO DRIVE GROWTH 121
TABLE 47 MAJOR ISH TESTS/KITS AVAILABLE 122
TABLE 48 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022–2029 (USD MILLION) 122
TABLE 49 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 50 EUROPE: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 51 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION) 124
TABLE 52 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION) 124
7.4 NEXT-GENERATION SEQUENCING 124
7.4.1 ADVANTAGES SUCH AS ACCURACY, SENSITIVITY, AND SPEED TO SUPPORT MARKET GROWTH 124
TABLE 53 MAJOR NGS TESTS/KITS AVAILABLE 125
TABLE 54 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2022–2029 (USD MILLION) 126
TABLE 55 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 126
TABLE 56 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 57 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 58 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 128
7.5 IMMUNOHISTOCHEMISTRY 128
7.5.1 INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES TO SUPPORT GROWTH 128
TABLE 59 MAJOR IHC TESTS/KITS AVAILABLE 129
TABLE 60 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2022–2029 (USD MILLION) 129
TABLE 61 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 62 EUROPE: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 63 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 64 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION) 131
7.6 OTHER TECHNOLOGIES 131
TABLE 65 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION) 132
TABLE 66 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 67 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 68 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 69 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION) 134
8 COMPANION DIAGNOSTICS MARKET, BY INDICATION 135
8.1 INTRODUCTION 136
TABLE 70 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 136
8.2 CANCER 136
TABLE 71 ESTIMATED NUMBER OF CANCER CASES, BY REGION, 2022 VS. 2040 137
TABLE 72 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 137
TABLE 73 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION) 137
TABLE 74 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 75 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 76 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 77 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 139
8.2.1 LUNG CANCER 139
8.2.1.1 Growing demand for effective therapeutic drugs to increase CDx adoption 139
TABLE 78 ESTIMATED NUMBER OF LUNG CANCER CASES, BY REGION, 2022 VS. 2040 140
TABLE 79 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2022–2029 (USD MILLION) 141
TABLE 80 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 81 EUROPE: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 82 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 83 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 143
8.2.2 BREAST CANCER 143
8.2.2.1 Wide prevalence of breast cancer to boost market growth 143
TABLE 84 ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2022 VS. 2040 144
TABLE 85 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2022–2029 (USD MILLION) 144
TABLE 86 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 87 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 88 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 89 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 146
8.2.3 BLOOD CANCER 146
8.2.3.1 Growing incidence of blood cancer to drive market 146
TABLE 90 ESTIMATED NUMBER OF LEUKEMIA CASES, BY REGION, 2022 VS. 2040 147
TABLE 91 COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY REGION, 2022–2029 (USD MILLION) 147
TABLE 92 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 147
TABLE 93 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 94 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 95 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 149
8.2.4 COLORECTAL CANCER 149
8.2.4.1 Rising need for molecular profiling of primary tumors to drive segment growth 149
TABLE 96 ESTIMATED NUMBER OF COLORECTAL CANCER CASES, BY REGION, 2022 VS. 2040 150
TABLE 97 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2022–2029 (USD MILLION) 150
TABLE 98 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 150
TABLE 99 EUROPE: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 151
TABLE 100 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 151
TABLE 101 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 152
8.2.5 OTHER CANCERS 152
TABLE 102 COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2022–2029 (USD MILLION) 152
TABLE 103 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 104 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 105 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 106 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION) 154
8.3 NEUROLOGICAL DISEASES 154
8.3.1 GROWING NUMBER OF ADVANCED TECHNOLOGIES TO BOOST ADOPTION OF COMPANION DIAGNOSTICS 154
TABLE 107 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION) 155
TABLE 108 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 109 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 156
TABLE 110 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 156
TABLE 111 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 157
8.4 CARDIOVASCULAR DISEASES 157
8.4.1 INCREASING DEMAND FOR TARGETED THERAPIES TO DRIVE SEGMENT GROWTH 157
TABLE 112 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022–2029 (USD MILLION) 158
TABLE 113 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 114 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 115 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 116 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 160
8.5 INFECTIOUS DISEASES 160
8.5.1 INCREASING AWARENESS OF TARGETED THERAPIES TO PROPEL GROWTH 160
TABLE 117 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION) 161
TABLE 118 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 119 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 120 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 121 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 163
8.6 OTHER INDICATIONS 163
TABLE 122 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2029 (USD MILLION) 163
TABLE 123 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 124 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 125 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 165
TABLE 126 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 165
9 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE 166
9.1 INTRODUCTION 167
TABLE 127 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 167
9.2 TISSUE SAMPLES 167
9.2.1 COMPREHENSIVE PROFILING AND HIGH SENSITIVITY TO DRIVE MARKET 167
TABLE 128 EXAMPLES OF FDA-APPROVED TISSUE-BASED COMPANION DIAGNOSTIC PRODUCTS 168
TABLE 129 COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY REGION, 2022–2029 (USD MILLION) 168
TABLE 130 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 169
TABLE 131 EUROPE: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 169
TABLE 132 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 133 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 170
9.3 BLOOD SAMPLES 170
9.3.1 LESS INVASIVE METHOD—KEY FACTOR DRIVING ADOPTION 170
TABLE 134 EXAMPLES OF FDA-APPROVED BLOOD-BASED COMPANION DIAGNOSTIC PRODUCTS 171
TABLE 135 COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2022–2029 (USD MILLION) 171
TABLE 136 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 172
TABLE 137 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 172
TABLE 138 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 139 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 173
9.4 OTHER SAMPLE TYPES 173
TABLE 140 EXAMPLES OF OTHER SAMPLE-BASED COMPANION DIAGNOSTIC PRODUCTS 174
TABLE 141 COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2022–2029 (USD MILLION) 174
TABLE 142 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 143 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION) 175
TABLE 144 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION) 175
TABLE 145 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION) 176
10 COMPANION DIAGNOSTICS MARKET, BY END USER 177
10.1 INTRODUCTION 178
TABLE 146 COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 178
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 178
10.2.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE MARKET 178
TABLE 147 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION) 179
TABLE 148 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 179
TABLE 149 EUROPE: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 180
TABLE 150 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 180
TABLE 151 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 181
10.3 REFERENCE LABORATORIES 181
10.3.1 RISING DEMAND FOR TARGETED THERAPIES TO DRIVE GROWTH 181
TABLE 152 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2022–2029 (USD MILLION) 182
TABLE 153 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 154 EUROPE: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 183
TABLE 155 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 183
TABLE 156 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 184
10.4 CONTRACT RESEARCH ORGANIZATIONS 184
10.4.1 RISING DEMAND FOR COMPANION DIAGNOSTIC PRODUCTS FOR USE IN THERAPY-RELATED CLINICAL TRIALS TO PROPEL GROWTH 184
TABLE 157 COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION) 185
TABLE 158 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 185
TABLE 159 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 160 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 161 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 187
10.5 OTHER END USERS 187
TABLE 162 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION) 188
TABLE 163 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 164 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 189
TABLE 165 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 189
TABLE 166 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 190
11 COMPANION DIAGNOSTICS MARKET, BY REGION 191
11.1 INTRODUCTION 192
TABLE 167 COMPANION DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 192
11.2 NORTH AMERICA 192
TABLE 168 NUMBER OF NEW CANCER CASES IN NORTH AMERICA, BY TYPE OF CANCER, 2022 VS. 2045 193
FIGURE 32 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT 194
TABLE 169 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 170 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 195
TABLE 171 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 195
TABLE 172 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 196
TABLE 173 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 196
TABLE 174 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 197
TABLE 175 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 197
11.2.1 NORTH AMERICA: RECESSION IMPACT 197
11.2.2 US 198
11.2.2.1 Increasing use of companion diagnostics for cancer treatment to boost market growth 198
TABLE 176 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040 199
TABLE 177 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 199
TABLE 178 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 199
TABLE 179 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 200
TABLE 180 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 200
TABLE 181 US: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 201
TABLE 182 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 201
11.2.3 CANADA 201
11.2.3.1 Increasing government initiatives to drive market 201
TABLE 183 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040 202
TABLE 184 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 203
TABLE 185 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 203
TABLE 186 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 204
TABLE 187 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 188 CANADA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 205
TABLE 189 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 205
11.3 EUROPE 205
TABLE 190 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 206
TABLE 191 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 207
TABLE 192 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 207
TABLE 193 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 208
TABLE 194 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 208
TABLE 195 EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 209
TABLE 196 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 209
11.3.1 EUROPE: RECESSION IMPACT 209
11.3.2 GERMANY 210
11.3.2.1 Increasing healthcare expenditure to drive market 210
TABLE 197 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 211
TABLE 198 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 211
TABLE 199 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 212
TABLE 200 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 201 GERMANY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 213
TABLE 202 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 213
11.3.3 UK 213
11.3.3.1 Growing life science industry and increasing focus on research to propel market 213
TABLE 203 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 214
TABLE 204 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 215
TABLE 205 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 215
TABLE 206 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 216
TABLE 207 UK: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 216
TABLE 208 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 217
11.3.4 SWITZERLAND 217
11.3.4.1 Strong research-oriented pharma industry to support market growth 217
TABLE 209 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 218
TABLE 210 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 218
TABLE 211 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 219
TABLE 212 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 219
TABLE 213 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 220
TABLE 214 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 220
11.3.5 FRANCE 220
11.3.5.1 Increasing government funding for research to support market growth 220
TABLE 215 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 221
TABLE 216 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 222
TABLE 217 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 222
TABLE 218 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 219 FRANCE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 223
TABLE 220 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 224
11.3.6 ITALY 224
11.3.6.1 Growing geriatric population in region to drive market 224
TABLE 221 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 225
TABLE 222 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 225
TABLE 223 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 226
TABLE 224 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 226
TABLE 225 ITALY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 227
TABLE 226 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 227
11.3.7 SPAIN 227
11.3.7.1 Increasing focus on advancement of personalized medicine to drive market growth 227
TABLE 227 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 228
TABLE 228 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 229
TABLE 229 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 229
TABLE 230 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 230
TABLE 231 SPAIN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 230
TABLE 232 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 231
11.3.8 REST OF EUROPE 231
TABLE 233 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 232
TABLE 234 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 232
TABLE 235 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 233
TABLE 236 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 233
TABLE 237 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 234
TABLE 238 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 234
11.4 ASIA PACIFIC 235
FIGURE 33 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT 236
TABLE 239 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 237
TABLE 240 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 237
TABLE 241 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 238
TABLE 242 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 238
TABLE 243 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 239
TABLE 244 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 239
TABLE 245 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 240
11.4.1 ASIA PACIFIC: RECESSION IMPACT 240
11.4.2 CHINA 240
11.4.2.1 Advancements in healthcare facilities to drive market 240
TABLE 246 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040 241
TABLE 247 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 241
TABLE 248 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 242
TABLE 249 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 242
TABLE 250 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 243
TABLE 251 CHINA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 243
TABLE 252 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 244
11.4.3 JAPAN 244
11.4.3.1 Increasing research initiatives to support market growth 244
TABLE 253 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040 244
TABLE 254 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 245
TABLE 255 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 245
TABLE 256 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 246
TABLE 257 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 246
TABLE 258 JAPAN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 247
TABLE 259 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 247
11.4.4 INDIA 247
11.4.4.1 Increased demand for early cancer diagnosis to fuel market growth 247
TABLE 260 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040 248
TABLE 261 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 249
TABLE 262 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 249
TABLE 263 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 250
TABLE 264 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 250
TABLE 265 INDIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 251
TABLE 266 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 251
11.4.5 AUSTRALIA 251
11.4.5.1 Initiatives to enhance healthcare access and infrastructure for aging population to drive market 251
TABLE 267 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 252
TABLE 268 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 253
TABLE 269 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 253
TABLE 270 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 254
TABLE 271 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 254
TABLE 272 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 255
11.4.6 REST OF ASIA PACIFIC 255
TABLE 273 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 256
TABLE 274 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 256
TABLE 275 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 257
TABLE 276 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 257
TABLE 277 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 258
TABLE 278 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 258
11.5 LATIN AMERICA 258
TABLE 279 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 259
TABLE 280 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 259
TABLE 281 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 260
TABLE 282 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 260
TABLE 283 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 261
TABLE 284 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 261
TABLE 285 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 262
11.5.1 LATIN AMERICA: RECESSION IMPACT 262
11.5.2 BRAZIL 262
11.5.2.1 Increasing incidence of lifestyle diseases to favor market growth 262
TABLE 286 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 263
TABLE 287 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 263
TABLE 288 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 264
TABLE 289 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 264
TABLE 290 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 265
TABLE 291 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 265
11.5.3 MEXICO 265
11.5.3.1 Growing medical tourism to fuel demand for companion diagnostics 265
TABLE 292 MEXICO: NEW CANCER CASES, 2022 266
TABLE 293 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 266
TABLE 294 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 267
TABLE 295 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 267
TABLE 296 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 268
TABLE 297 MEXICO: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 268
TABLE 298 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 269
11.5.4 REST OF LATIN AMERICA 269
TABLE 299 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 269
TABLE 300 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 270
TABLE 301 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 270
TABLE 302 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 271
TABLE 303 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 271
TABLE 304 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 272
11.6 MIDDLE EAST & AFRICA 272
11.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET GROWTH 272
TABLE 305 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 273
TABLE 306 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 273
TABLE 307 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 274
TABLE 308 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 274
TABLE 309 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 275
TABLE 310 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 275
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 275
11.7 GCC COUNTRIES 276
11.7.1 GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH 276
TABLE 311 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 276
TABLE 312 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 277
TABLE 313 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION) 277
TABLE 314 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION) 278
TABLE 315 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION) 278
TABLE 316 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 279
11.7.2 GCC COUNTRIES: RECESSION IMPACT 279
12 COMPETITIVE LANDSCAPE 280
12.1 INTRODUCTION 280
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 280
TABLE 317 COMPANION DIAGNOSTICS MARKET: STRATEGIES ADOPTED 280
12.3 REVENUE SHARE ANALYSIS 282
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS (2019–2023) 282
12.4 MARKET SHARE ANALYSIS 282
FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023) 283
TABLE 318 COMPANION DIAGNOSTICS MARKET: DEGREE OF COMPETITION 283
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 284
12.5.1 STARS 284
12.5.2 EMERGING LEADERS 284
12.5.3 PERVASIVE PLAYERS 284
12.5.4 PARTICIPANTS 285
FIGURE 36 COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 285
12.5.5 COMPANY FOOTPRINT 286
12.5.5.1 Overall footprint 286
FIGURE 37 COMPANION DIAGNOSTICS MARKET: OVERALL FOOTPRINT 286
12.5.5.2 Product footprint 286
TABLE 319 COMPANION DIAGNOSTICS MARKET: PRODUCT FOOTPRINT 286
12.5.5.3 Technology footprint 287
TABLE 320 COMPANION DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT 287
12.5.5.4 Indication footprint 287
TABLE 321 COMPANION DIAGNOSTICS MARKET: INDICATION FOOTPRINT 287
12.5.5.5 Regional footprint 288
TABLE 322 COMPANION DIAGNOSTICS MARKET: REGIONAL FOOTPRINT 288
12.6 COMPETITIVE EVALUATION MATRIX: START-UPS/SMES 288
12.6.1 PROGRESSIVE COMPANIES 288
12.6.2 RESPONSIVE COMPANIES 288
12.6.3 DYNAMIC COMPANIES 288
12.6.4 STARTING BLOCKS 289
FIGURE 38 COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023 289
12.6.5 COMPETITIVE BENCHMARKING 290
TABLE 323 COMPANION DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES 290
TABLE 324 COMPANION DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES 290
12.7 VALUATION AND FINANCIAL METRICS OF COMPANION DIAGNOSTICS VENDORS 291
FIGURE 39 EV/EBITDA OF KEY VENDORS 291
FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 291
12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 292
FIGURE 41 PRODUCT/BRAND COMPARATIVE ANALYSIS, BY PARAMETER 292
12.8.1 F. HOFFMANN-LA ROCHE LTD. 292
12.8.2 AGILENT TECHNOLOGIES, INC. 292
12.8.3 QIAGEN 292
12.8.4 THERMO FISHER SCIENTIFIC INC. 293
12.8.5 ABBOTT 293
12.9 COMPETITIVE SCENARIO 293
12.9.1 PRODUCT LAUNCHES & APPROVALS 293
TABLE 325 COMPANION DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2024 293
12.9.2 DEALS 294
TABLE 326 COMPANION DIAGNOSTICS MARKET: DEALS, JANUARY 2021–MARCH 2024 294
13 COMPANY PROFILES 295
(Business Overview, Products/Services/Solutions Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1 KEY PLAYERS 295
13.1.1 F. HOFFMANN-LA ROCHE LTD. 295
TABLE 327 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 295
FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023) 296
TABLE 328 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 296
TABLE 329 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS 299
TABLE 330 F. HOFFMANN-LA ROCHE LTD.: DEALS 300
13.1.2 AGILENT TECHNOLOGIES, INC. 302
TABLE 331 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 302
FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023) 303
TABLE 332 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 303
TABLE 333 AGILENT TECHNOLOGIES, INC.: PRODUCT APPROVALS 305
TABLE 334 AGILENT TECHNOLOGIES, INC.: DEALS 306
13.1.3 QIAGEN 307
TABLE 335 QIAGEN: COMPANY OVERVIEW 307
FIGURE 44 QIAGEN: COMPANY SNAPSHOT (2023) 308
TABLE 336 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED 308
TABLE 337 QIAGEN: PRODUCT LAUNCHES & APPROVALS 310
TABLE 338 QIAGEN: DEALS 310
13.1.4 THERMO FISHER SCIENTIFIC INC. 312
TABLE 339 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 312
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 313
TABLE 340 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 313
TABLE 341 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS 316
TABLE 342 THERMO FISHER SCIENTIFIC INC.: DEALS 317
13.1.5 ABBOTT 318
TABLE 343 ABBOTT: COMPANY OVERVIEW 318
FIGURE 46 ABBOTT: COMPANY SNAPSHOT (2023) 319
TABLE 344 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED 319
13.1.6 DANAHER 322
TABLE 345 DANAHER: COMPANY OVERVIEW 322
FIGURE 47 DANAHER: COMPANY SNAPSHOT (2023) 323
TABLE 346 DANAHER: PRODUCTS/SERVICES/SOLUTIONS OFFERED 324
13.1.7 GUARDANT HEALTH 325
TABLE 347 GUARDANT HEALTH: COMPANY OVERVIEW 325
FIGURE 48 GUARDANT HEALTH: COMPANY SNAPSHOT (2023) 326
TABLE 348 GUARDANT HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED 326
TABLE 349 GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS 327
TABLE 350 GUARDANT HEALTH: DEALS 328
TABLE 351 GUARDANT HEALTH: OTHER DEVELOPMENTS 328
13.1.8 ILLUMINA, INC. 329
TABLE 352 ILLUMINA, INC.: COMPANY OVERVIEW 329
FIGURE 49 ILLUMINA, INC.: COMPANY SNAPSHOT (2023) 330
TABLE 353 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 330
TABLE 354 ILLUMINA, INC.: PRODUCT LAUNCHES 331
TABLE 355 ILLUMINA, INC.: DEALS 331
13.1.9 BIOMÉRIEUX 333
TABLE 356 BIOMÉRIEUX: COMPANY OVERVIEW 333
FIGURE 50 BIOMÉRIEUX: COMPANY SNAPSHOT (2023) 334
TABLE 357 BIOMÉRIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED 334
13.1.10 ICON PLC 335
TABLE 358 ICON PLC: COMPANY OVERVIEW 335
FIGURE 51 ICON PLC: COMPANY SNAPSHOT (2023) 335
TABLE 359 ICON PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED 336
13.1.11 MYRIAD GENETICS, INC. 337
TABLE 360 MYRIAD GENETICS, INC.: COMPANY OVERVIEW 337
FIGURE 52 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2023) 338
TABLE 361 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 338
TABLE 362 MYRIAD GENETICS, INC.: PRODUCT APPROVALS 339
TABLE 363 MYRIAD GENETICS, INC.: DEALS 339
13.1.12 SYSMEX CORPORATION 340
TABLE 364 SYSMEX CORPORATION: COMPANY OVERVIEW 340
FIGURE 53 SYSMEX CORPORATION: COMPANY SNAPSHOT (2023) 341
TABLE 365 SYSMEX CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 341
TABLE 366 SYSMEX CORPORATION: DEALS 342
TABLE 367 SYSMEX CORPORATION: OTHER DEVELOPMENTS 342
13.2 OTHER PLAYERS 343
13.2.1 ALMAC GROUP 343
TABLE 368 ALMAC GROUP: COMPANY OVERVIEW 343
13.2.2 ARUP LABORATORIES 344
TABLE 369 ARUP LABORATORIES: COMPANY OVERVIEW 344
13.2.3 ABNOVA CORPORATION 345
TABLE 370 ABNOVA CORPORATION: COMPANY OVERVIEW 345
13.2.4 BIOGENEX 346
TABLE 371 BIOGENEX: COMPANY OVERVIEW 346
13.2.5 INVIVOSCRIBE, INC. 347
TABLE 372 INVIVOSCRIBE, INC.: COMPANY OVERVIEW 347
13.2.6 ARCHERDX, INC. 348
TABLE 373 ARCHERDX, INC.: COMPANY OVERVIEW 348
13.2.7 Q² SOLUTIONS 349
TABLE 374 Q² SOLUTIONS: COMPANY OVERVIEW 349
13.2.8 AMOY DIAGNOSTICS CO., LTD. 350
TABLE 375 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW 350
13.2.9 UNIOGEN 351
TABLE 376 UNIOGEN: COMPANY OVERVIEW 351
13.2.10 ASURAGEN, INC. 352
TABLE 377 ASURAGEN, INC.: COMPANY OVERVIEW 352
13.2.11 MESO SCALE DIAGNOSTICS, LLC 353
TABLE 378 MESO SCALE DIAGNOSTICS, LLC: COMPANY OVERVIEW 353
13.2.12 CREATIVE BIOLABS 354
TABLE 379 CREATIVE BIOLABS: COMPANY OVERVIEW 354
13.2.13 NG BIOTECH 355
TABLE 380 NG BIOTECH: COMPANY OVERVIEW 355
*Details on Business Overview, Products/Services/Solutions Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX 356
14.1 DISCUSSION GUIDE 356
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 361
14.3 CUSTOMIZATION OPTIONS 363
14.4 RELATED REPORTS 363
14.5 AUTHOR DETAILS 364
Table of Contents